Trending...
- Talaria E-bike China Source Cuts Talaria Sting MX5 Pro Pricing by $700 - 147
- Long Beach to Launch Time Capsule Honoring America's 250th Anniversary as Part of 908 Day Celebration
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
HAYWARD, Calif., Feb. 3, 2023 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023. Since its founding, Avirmax Biopharma Inc (ABI) has been focusing on developing an effective gene therapy product, ABI-902 for glaucoma treatment. Intravitreal administration of ABI-902 has demonstrated retinal ganglion cell (RGC) protection against N-methyl-D-Asparate (NMDA) excitotoxicity in mice and rats of partial optic nerve transection (pONT) measured by Detection of Apoptosing Retinal Cell (DARC) imaging technology. ABI-902 is manufactured by Avirmax CMC Inc.
Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
More on The Californer
Glaucoma is the second largest eye disease that leads to blindness in advanced stages. About 3 million individuals in USA and 80 million individuals worldwide are affected and the number expected to rise to 111 million globally by 2040. The main mechanism for glaucoma-induced blindness is the irreversible death of RGCs. Human eye has ~1.2 to 1.5 million RGCs which will never regenerate after glaucoma-related cell death. Drugs available in market target the IOP reduction and slow down the RGC death. Hopes for better treatment of glaucoma patients reside in protecting RGCs and lowering IOP simultaneously.
Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine. Avirmax Inc. specializes in developing rAAV mediated therapeutics for ocular diseases using its proprietary protein and rAAV engineering technologies. Visit us at avirmaxBP.com for more information.
Contact
Please contact
June Song, Associate Director for Operations
Email : [email protected]
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
SOURCE Avirmax
Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
More on The Californer
- Free National Summit Empowers Animal Advocacy
- Dodge Hornet Lemon Law Attorney in Los Angeles County
- 'Nightmare' Star Mckenna Bridger Talks Psychological Thriller, Two-Part Shoot And Taking On Violet Adams
- Mckenna Bridger on Becoming Violet Adams in Nightmare
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
Glaucoma is the second largest eye disease that leads to blindness in advanced stages. About 3 million individuals in USA and 80 million individuals worldwide are affected and the number expected to rise to 111 million globally by 2040. The main mechanism for glaucoma-induced blindness is the irreversible death of RGCs. Human eye has ~1.2 to 1.5 million RGCs which will never regenerate after glaucoma-related cell death. Drugs available in market target the IOP reduction and slow down the RGC death. Hopes for better treatment of glaucoma patients reside in protecting RGCs and lowering IOP simultaneously.
Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine. Avirmax Inc. specializes in developing rAAV mediated therapeutics for ocular diseases using its proprietary protein and rAAV engineering technologies. Visit us at avirmaxBP.com for more information.
Contact
Please contact
June Song, Associate Director for Operations
Email : [email protected]
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
SOURCE Avirmax
Filed Under: Business
0 Comments
Latest on The Californer
- Best Lemon Law Attorney in Rowland Heights CA
- Thursday's Hair Solutions Celebrates Alopecia Awareness Month This September
- Responsive Web Designs Services in San Diego Drive Digital Growth
- California: On September 11, Governor Newsom welcomes CAL FIRE's newest leaders as they answer the call to serve
- Kindness Village to Build a New Model for Attainable Housing
- The Best Policy Administration System for Small-to-Mid Size Insurers & MGAs
- California: Governor Newsom proclaims Patriot Day
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- City of Long Beach Extends Heat Alert, Advises Residents to Take Precautions Against Heat
- iDAREcares and Majapahit Martial Arts Bring Silat & Kali to Indonesian Celebration in Los Angeles
- Emmy Nominee Sepideh Moafi And Peabody Award Winner Aasif Mandvi To Receive Cultural Impact Awards
- Anglepoint Named to Fast Company's 2026 Best Workplaces for Innovators List
- Wavymy New-In Glueless Wig: Blowout Wave 7x5 Glueless Bob Wig
- Gateway Oaks Dental Marks 18th Year in Sacramento by Investing in Modern Dental Technology
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- AI Biological Weapon Concerns Increase Focus on CBRN Protection for Private Shelters
- Designer-Inspired Jewellery Gifts: Timeless Pieces for Every Occasion
- Build a Stronger Online Presence with Strategic Web Design & Development
- California: What they are saying: National leaders and lawmakers celebrate Governor Newsom's signature on landmark child safety chatbot and social media laws